RNA polymerase II CTD [8A7]

GWB-225CEF

IgM

RNA polymerase II CTD

NoneConstituents: PBS

217 kDa. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user. Myeloma: Sp2/0-Ag14 RNA polymerase II carboxy-terminal domain (CTD) interacts with a large multisubunit complex that contains TATA-binding protein (TBP) and is an integral part of the transcription initiation complex. Phosphorylation of RNA polymerase II\' s largest subunit C-terminal domain (CTD) is a key event during mRNA metabolism. Numerous enzymes including cell cycle-dependent kinases and TFIIF-dependent phosphatases target the CTD.

Chromosomal aberrations involving IGHG1 may be a cause of multiple myeloma [MIM:254500]. Translocation t(11; 14)(q13; q32) with CCND1; translocation t(4; 14)(p16. 3; q32. 3) with FGFR3; translocation t(6; 14)(p25; q32) with IRF4.

Nie also differs in the amidation states of 35 116 198 269 and 272.

KOL also differs in the amidation states of residues 198 267 and 272.